| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
David McIntyre is Chief Financial Officer at RCEL. David McIntyre's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $14K at current prices.
Net of sales, the RCEL filings show accumulation of 693 shares.
David McIntyre has 3 Form 4 filings on record from July 2020 to January 2026, across 2 companies: Chief Financial Officer at Inhibikase Therapeutics (IKT), 2025–2026; Chief Financial Officer at AVITA Medical (RCEL), 2020.
The 4 reported transactions were 2 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 1 purchase worth about $16K and no sales.
The only open-market purchase was 693 shares of RCEL at an average $23.20 on July 17, 2020, about $16K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 17, 2020 | RCEL Avita Medical, Inc. | Chief Financial Officer | Buy | 693 | $23.20 | $16,076.10 | +346.5% |